Top

Published in:

01-06-2011 | Letter

Nonepithelial, submucosal gastric tumors: is laparoscopic wedge resection the optimal treatment?

Authors: Odysseas Zoras, John Spiliotis

Published in: Surgical Endoscopy | Issue 6/2011

Excerpt

Adenocarcinomas are the most common tumors of the stomach, whereas nonepithelial stromal tumors of the stomach are rare. Open surgery, usually gastrectomy, is the standard of care for these tumors. With rapid advances in laparoscopic surgery for gastric cancer and lack of evidence for the necessity of lymphadenectomy, new surgical strategies are evaluated for the treatment of these submucosal tumors, but data on this subject still are scarce. …

Ke CW, Cai JL, Chen DL, Zheng CZ (2010) Extraluminal laparoscopic wedge resection of gastric submucosal tumors: a retrospective review of 84 cases. Surg Endosc 24:1962–1968PubMedCrossRef

Ziogas D, Polychronidis A, Kanellos I, Roukos D (2009) Laparoscopic colectomy survival benefit for colon cancer: is evidence from a randomized trial true? Ann Surg 249:695–696PubMedCrossRef

Ziogas D, Roukos D (2008) Robotic surgery for rectal cancer: may it improve also survival? Surg Endosc 22:1405–1406PubMedCrossRef

Bali C, Ziogas D, Roukos DH, Baltogiannis G (2010) Laparoscopic and robotic rectal cancer resection: expectations for improving oncological outcomes. Ann Surg 251:185–186CrossRef

Katsios GC, Baltogiannis G, Roukos DH (2010) Laparoscopic surgery for gastric cancer: comparative-effectiveness research and future trends. Expert Rev Anticancer Ther 10:473–476PubMedCrossRef

Liakakos T, Roukos DH (2009) Randomized evidence for laparoscopic gastrectomy short-term quality-of-life improvement and challenges for improving long-term outcomes. Ann Surg 250:349–350PubMedCrossRef

Liakakos T, Roukos D (2008) Laparoscopic gastrectomy: advances enable wide clinical application. Surg Endosc 22:1553–1555PubMedCrossRef

Liakakos T, Roukos DH (2008) Is there any long-term benefit in quality of life after laparoscopy-assisted distal gastrectomy for gastric cancer? Surg Endosc 22:1402–1404PubMedCrossRef

Roukos DH (2009) Laparoscopic gastrectomy and personal genomics: high-volume surgeons and predictive biomedicine may govern the future for resectable gastric cancer. Ann Surg 250:650–651PubMedCrossRef

10.

Roukos DH (2009) Genome-wide association studies and aggressive surgery toward individualized prevention, and improved local control and overall survival for gastric cancer. Ann Surg Oncol 164:795–798CrossRef

11.

Roukos DH, Paraschou P, Lorenz M (2000) Distal gastric cancer and extensive surgery: a new evaluation method based on the study of the status of residual lymph nodes after limited surgery. Ann Surg Oncol 7:719–726PubMedCrossRef

12.

Roukos DH (2010) Systems medicine: a real approach for future personalized oncology? Pharmacogenomics 11:283–287PubMedCrossRef

13.

Roukos DH (2010) Novel clinico-genome network modeling for revolutionizing genotype–phenotype-based personalized cancer care. Expert Rev Mol Diagn 10:33–48PubMedCrossRef

14.

Roukos DH (2009) Isolated tumor cells in breast cancer. N Engl J Med 361:1994–1995PubMedCrossRef

15.

Ziogas D, Roukos DH (2009) Genetics and personal genomics for personalized breast cancer surgery: progress and challenges in research and clinical practice. Ann Surg Oncol 16:1771–1782PubMedCrossRef

16.

Roukos DH, Lykoudis E, Liakakos T (2008) Genomics and challenges toward personalized breast cancer local control. J Clin Oncol 26:4360–4361PubMedCrossRef

17.

Roukos DH, Ziogas D (2009) Human genetic and structural genomic variation: would genome-wide association studies be the solution for cancer complexity like Alexander the Great for the “Gordian Knot”? Ann Surg Oncol 16:774–775PubMedCrossRef

18.

Roukos DH (2010) Targeting gastric cancer with trastuzumab: new clinical practice and innovative developments to overcome resistance. Ann Surg Oncol 17:14–17PubMedCrossRef

19.

Ziogas D, Roukos DH (2009) CDH1 testing: can it predict the prophylactic or therapeutic nature of total gastrectomy in hereditary diffuse gastric cancer? Ann Surg Oncol 16:2678–2681PubMedCrossRef

20.

Roukos DH (2010) Next-generation sequencing and epigenome technologies: potential medical applications. Expert Rev Med Devices 7(6):723–726PubMedCrossRef

21.

Roukos DH, Ziogas DE, Katsios C (2010) Multigene assays and isolated tumor cells for early breast cancer treatment: time for bionetworks. Expert Rev Anticancer Ther 10(8):1187–1195PubMedCrossRef

22.

Roukos DH (2010) Complete genome sequencing and network modeling to overcome trastuzumab resistance. Pharmacogenomics 11(8):1039–1043PubMedCrossRef

23.

Roukos DH (2010) Next-generation, genome sequencing-based biomarkers: concerns and challenges for medical practice. Biomark Med 4(4):583–586PubMedCrossRef

24.

Katsios C, Roukos DH (2010) Individual genomes and personalized medicine: life diversity and complexity. Per Med 7(4):347–350CrossRef

25.

Roukos DH, Katsios C, Liakakos T (2010) Genotypephenotype map and molecular networks: a promising solution in overcoming colorectal cancer resistance to targeted treatment. Expert Rev Mol Diagn 10(5):541–545PubMedCrossRef

26.

Roukos DH (2010) Bionetworks-based personalized medicine versus comparative-effectiveness research or harmonization of both in cancer management? Expert Rev Mol Diagn 10(3):247–250PubMedCrossRef

27.

Roukos DH, Ziogas D (2010) From tumor size and HER2 status to systems oncology for very early breast cancer treatment. Expert Rev Anticancer Ther 10(2):123–128PubMedCrossRef

28.

Roukos DH, Tzakos A, Zografos G (2009) Current concerns and challenges towards tailored antiangiogenic therapy in cancer. Expert Rev Anticancer Ther 9(10):1413–1416PubMedCrossRef

29.

Roukos DH (2009) Radiation therapy for breast cancer. N Engl J Med 360(13):1362; author reply 1363

30.

Roukos DH, Kappas AM, Agnantis NJ (2003) Perspectives and risks of breast-conservation therapy for breast cancer. Ann Surg Oncol 10:718–721PubMedCrossRef

31.

Roukos DH, Kappas AM, Tsianos E (2002) Role of surgery in the prophylaxis of hereditary cancer syndromes. Ann Surg Oncol 9(7):607–609PubMedCrossRef

32.

Katsios C, Ziogas DE, Roukos DH (2010) Colorectal cancer: cetuximab, KRAS, BRAF, PIK3CA mutations and beyond. Expert Rev Gastroenterol Hepatol 4(5):525–529PubMedCrossRef

33.

Roukos DH (2010) Trastuzumab and beyond: sequencing cancer genomes and predicting molecular networks. Pharmacogenomics J. doi:10.1038/tpj.2010.81

34.

Roukos DH (2010) Cancer genome explosion and systems biology: Impact on surgical oncology? Ann Surg Oncol. doi:10.1245/s10434-010-1355-y

Title: Nonepithelial, submucosal gastric tumors: is laparoscopic wedge resection the optimal treatment?
Authors: Odysseas Zoras
John Spiliotis
Publication date: 01-06-2011
Publisher: Springer-Verlag
Published in: Surgical Endoscopy / Issue 6/2011
Print ISSN: 0930-2794
Electronic ISSN: 1432-2218
DOI: https://doi.org/10.1007/s00464-010-1447-6

At a glance: The STEP trials

Springer Medicine

Nonepithelial, submucosal gastric tumors: is laparoscopic wedge resection the optimal treatment?

Excerpt

At a glance: The STEP trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 6/2011

Learning curve for laparoscopic repair of very large hiatal hernia

Single-incision laparoscopic versus conventional laparoscopic right hemicolectomy: a comparison of short-term surgical results

Clinical and pH-metric outcomes of transoral esophagogastric fundoplication for the treatment of gastroesophageal reflux disease

Downregulation of leptin and resistin expression in blood following bariatric surgery

Laparoscopic restorative proctocolectomy with ileal pouch-anal anastomosis for ulcerative colitis and impact of anti-tumor necrosis factor on postoperative outcomes

Plasma levels of angiostatin and endostatin remain unchanged for the first 3 weeks after colorectal cancer surgery